Molecular mechanisms of hepatitis C virus, potential therapeutic targets;Mecanismos moleculares del virus de la hepatitis C, potenciales blancos terapéuticos

Revista de Investigacion Clinica

Volumn 55, Issue 1, 2003, Pages 51-64

  Rivas Estilla, Ana María ^a   Panduro, Arturo ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Hepatitis C; Hepatitis C virus (HCV); IRES; Protein translation; Recombinant DNA

Indexed keywords

ANTIVIRUS AGENT; DNA VACCINE; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS RNA;

DRUG TARGETING; FLAVIVIRUS; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL RESEARCH; MOLECULAR BIOLOGY; MOLECULAR CLONING; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; VIRUS ENVELOPE; VIRUS GENE; VIRUS GENOME; VIRUS INHIBITION; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION;

ANIMALS; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C; HUMANS; VIRUS REPLICATION;

EID: 0038076230     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Choo QL, Kuo GF, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer L, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
3. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: S34-S38.
4. Blum HE. Does hepatitis C virus cause hepatocellular carcinoma? Hepatology 1994; 19: 251-5.
5. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 704-7.
6. Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 1973; 182: 1026-8.
7. Blumberg BS, Gerstley BJ, Hungerford DF, London WT, Sutnick Al. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967; 66: 924-31.
8. Bradley DW, Maynard JE, McCaustland KA, Murphy BL, Cook EH, Ebert JW. Non-A, non-B hepatitis in chimpanzees: interference with acute hepatitis A virus and chronic hepatitis B virus infections. J Med Virol 1983; 11: 207-13.
9. He LF, Alling DF, Popkin TF, Shapiro MF, Alter HJ, Purcell RH. Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis 1987; 156: 636-40.
10. Bradley DW, McCaustland KA, Cook EH, Schable CA, Ebert JW, Maynard JE. Posttransfusion non-A, non-B hepatitis in chimpanzees. Physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology 1985; 88: 773-9.
11. Bradley DW, Maynard JE, Popper HF, Cook EH, Ebert JW, McCaustland KA, et al. Posttransfusion non-A, non-B hepatitis: physicochemical properties of two distinct agents. J Infect Dis 1983; 148: 254-65.
12. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-4.
13. Ohba K, Mizokami M, Lau JY, Orito E, Ikeo K, Gojobori T. Evolutionary relationship of hepatitis C, pesti-, flavi-, plant-viruses, and newly discovered GB hepatitis agents. FEBS Lett 1996; 378: 232-4.
14. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998; 143: 2493-503.
15. Linnen J, Wages J Jr., Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996; 271: 505-8.
16. Bartenschlager RF, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81: 1631-48.
17. Friebe P, Lohmann V, Krieger N, Bartenschlager R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J Virol 2001; 75: 12047-57.
18. Friebe P, Bartenschlager R. Genetic analysis of sequences in the 3′ nontranslated region of hepatitis C virus that are important for RNA replication. J Virol 2002; 76: 5326-38.
19. Pestova TV, Kolupaeva VG, Lomakin IB, Pilipenko EV, Shatsky IN, Agol VI, et al. Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci USA 2001; 98: 7029-36.
20. Pestova TV, Hellen CU, Shatsky IN. Canonical eukaryotic initiation factors determine initiation of translation by internal ribosomal entry. Mol Cell Biol 1996; 16: 6859-69.
21. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993; 67: 2832-43.
22. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993; 67: 1385-95.
23. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 2001; 313: 451-64.
24. Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000; 271: 197-204.
25. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappa B activation. J Virol 1999; 73: 4713-20.
26. Owsianka AM, Patel AH. Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. Virology 1999; 257: 330-40.
27. Erhardt A, Hassan M, Heintges T, Haussinger D. Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line. Virology 2002; 292: 272-84.
28. Aoki H, Hayashi J, Moriyama M, Arakawa Y, Hino O. Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1. J Virol 2000; 74: 1736-41.
29. Kato N, Yoshida H, Kioko Ono-Nita S, Kato J, Goto T, Otsuka M, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000; 32: 405-12.
30. Aiyama T, Yoshioka K, Okumura A, Takayanagi M, Iwata K, Ishikawa T, et al. Hypervariable region sequence in cryoglobulin-associated hepatitis C virus in sera of patients with chronic hepatitis C: relationship to antibody response against hypervariable region genome. Hepatology 1996; 24: 1346-50.
31. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-44.
32. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
33. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-10.
34. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993; 67: 3835-44.
35. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Virol Hepat 1999; 6: 165-81.
36. Di Marco S, Rizzi M, Volpari C, Walsh MA, Narjes F, Colarusso S, et al. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J Biol Chem 2000; 275: 7152-7.
37. Arima N, Kao CY, Licht T, Padmanabhan R, Sasaguri Y, Padmanabhan R. Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J Biol Chem 2001; 276: 12675-84.
38. Ghosh AK, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. Journal of General Virology 1999; 80: 1179-83.
39. Miyamura T. Interferon sensitivity determining sequence of the hepatitis C virus genome. Hepatology 1996; 24: 460-1.
40. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
41. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-30.
42. Fukuma T, Enomoto N, Marumo F, Sato C. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein. Hepatology 1998; 28: 1147-53.
43. Mihm S, Monazahian M, Grethe S, Meier V, Thomssen R, Ramadori G. Lack of clinical evidence for involvement of hepatitis C virus interferon-alpha sensitivity-determining region variability in RNA-dependent protein kinase-mediated cellular antiviral responses. J Med Virol 2000; 61: 29-36.
44. Gale MJ Jr., Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-27.
45. Gale M Jr., Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 5208-18.
46. Francois C, Duverlie G. Rebouillat D, Khorsi H, Castelain S, Blum HE, et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. Journal of Virol 2000; 74: 5587-96.
47. Rivas-Estilla AM, Svitkin Y, Lopez-Lastra M, Hatzoglou M, Sherker A, Koromilas AE. PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. J Virol 2002; Nov., in press.
48. Lesburg CA, Radfar RF, Weber PC. Recent advances in the analysis of HCV NS5B RNA-dependent RNA polymerase. Curr Opin Investig Drugs 2000; 1: 289-96.
49. Wang QM, Hockman MA, Staschke KF, Johnson RB, Case KA, Lu JF, et al. Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. J Virol 2002;76:3865-72.
50. Lohmann V, Roos A, Korner F, Koch JO, Bartenschlager R. Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology 1998; 249: 108-18.
51. Moradpour D, Bieck E, Hugle T, Wels W, Wu JZ, Hong Z, et al. Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 2002; 277: 593-601.
52. Ingravallo P, Lahser F, Xia E, Sodowich B, Lai VC, Hong Z, et al. Characterization of monoclonal antibodies that specifically recognize the palm subdomain of hepatitis C virus nonstructural protein 5B polymerase. Virus Res 2001; 75: 179-87.
53. Fang JW, Moyer RW. The effects of the conserved extreme 3′ end sequence of hepatitis C virus (HCV) RNA on the in vitro stabilization and translation of the HCV RNA genome. J Hepatol 2000; 33: 632-9.
54. Yanagi M, St Claire M, Emerson SU, Purcell RH, Bukh J. In vivo analysis of the 3′ untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci USA 1999; 96: 2291-5.
55. Forns X, Bukh J. The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin Liver Dis 1999; 3: 693-716.
56. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
57. Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 1994; 20: 1144-51.
58. Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992; 190: 894-9.
59. Nolte FS. Hepatitis C virus genotyping: Clinical implications and methods. Mol Diagn 2001; 6: 265-77.
60. Alvarez-Munoz MT, Vences-Aviles MA, Damacio L, Vazquez-Rosales G, Torres J, Gonzalez-Bravo F, et al. Hepatitis C virus RNA (HCV-RNA) in blood donors and family members seropositive for anfi-HCV antibodies. Arch Med Res 2001; 32: 442-5.
61. Rivas-Estilla AM, Sanchez L, Matsui O, Campollo O, Armendariz-Borunda J, Segura-Ortega JE, and Panduro A. Identification of Hepatitis C Virus (HCV) genotypes in infected patients from the west of Mexico. Hepatology Research 1998; 12: 121-30.
62. Bukh J, Miller RH. Diagnostic and clinical implications of the different genotypes of hepatitis C virus. Hepatology 1994; 20: 256-9.
63. Farci P. Hepatitis C virus. The importance of viral heterogeneity. Clin Liver Dis 2001; 5: 895-916.
64. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15: 82-91.
65. Lucey M, Traber PG. Detection of hepatitis C viral RNA by the polymerase chain reaction. Hepatology 1991;13: 193-5.
66. Lunel F, Cresta P, Vitour D, Payan C, Dumont B, Frangeul L, et al. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays. Hepatology 1999; 29: 528-35.
67. McGuinness PH, Bishop GA, Lien A, Wiley B, Parsons C, McCaughan GW. Detection of serum hepatitis C virus RNA in HCV antibody-seropositive volunteer blood donors. Hepatology 1993; 18: 485-90.
68. Negro F, Levrero M. Does the hepatitis C virus replicate in cells of the hematopoietic lineage? Hepatology 1998; 28: 261-4.
69. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler J, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999; 354: 1782-5.
70. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-71.
71. Thomssen RF, Bonk S, Propfe CF, Heermann KH, Kochel HG, et al Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 1992; 181: 293-300.
72. Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002; 36: 456-63.
73. Mizutani T, Kato N, Saito S, Ikeda M, Sugiyama K, Shimotohno K. Characterization of hepatitis C virus replication in cloned cells obtained from a human T-cell leukemia virus type 1-infected cell line, MT-2. J Virol 1996; 70: 7219-23.
74. Nakajima N, Hijikata M, Yoshikura H, Shimizu YK. Characterization of long-term cultures of hepatitis C virus. J Virol 1996; 70: 3325-9.
75. Fournier C, Sureau C, Coste J, Ducos J, Pageaux G, Larrey D, et al. In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. J Gen Virol 1998; 79: 2367-74.
76. Bartenschlager R. In vitro models for hepatitis C. Virus Res 2002; 82: 25-32.
77. Moradpour D, Kary P, Rice CM, Blum HE. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology 1998; 28: 192-201.
78. Myung J, Khalap N, Kalkeri G, Garry R, Dash S. Inducible model to study negative strand RNA synthesis and assembly of hepatitis C virus from a full-length cDNA clone. J Virol Methods 2001; 94: 55-67.
79. Lanford RE, Lee H, Chavez D, Guerra B, Brasky KM. Infectious cDNA clone of the hepatitis C virus genotype 1 prototype sequence. J Gen Viral 2001; 82: 1291-7.
80. Yoo BJ, Selby MJ, Choe J, Sub BS, Choi SH, Joh JS, et al. Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV. J Virol 1995; 69: 32-8.
81. Dash S, Halim AB, Tsuji HF, Hiramatsu NF, Gerber MA. Transfection of HepG2 cells with infectious hepatitis C virus genome. Am J Pathol 1997; 151: 363-73.
82. Beames B, Chavez D, Guerra B, Notvall L, Brasky KM, Lanford RE. Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus. J Viral 2000; 74: 11764-72.
83. Okamoto H, Mishiro S, Tokita H, Tsuda F, Miyakawa Y, Mayumi M. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a. Hepatology 1994; 20: 1131-6.
84. Mercer D, Schiller D, Elliott J, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-33.
85. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
86. Lanford RE, Bigger C. Advances in model systems for hepatitis C virus research. Virology 2002; 293: 1-9.
87. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-4.
88. Pietschmann T, Lehmann V, Kaul A, Krieger N, Rinck G, Rutter G, et al. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 2002; 76: 4008-21.
89. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-9.
90. Zeuzem S, Heathcote JE, Martin N, Nieforth K, Modi M. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin Investig Drugs 2001; 10: 2201-13.
91. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000; 32: 647-53.
92. Daugherty D. Genetic structure and heterogeneity of hepatitis C virus: a vaccine impediment? Hepatology 1992; 15: 739-41.
93. Dimasi N, Martin F, Volpari C, Brunetti M, Biasiol G, Altamura S, et al. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. J Virol 1997; 71: 7461-9.
94. Zhang RF, Durkin JP, Windsor WT. Azapeptides as inhibitors of the hepatitis C virus NS3 scrine protease. Bioorg Med Chem Lett 2002; 12: 1005-8.
95. Bukhtiyarova MF, Rizzo CJ, Kettner CA, Korant BD, Scarnati HT, King RW. Inhibition of the bovine viral diarrhoea virus NS3 serine protease by a boron-modified peptidyl mimetic of its natural substrate. Antivir Chem Chemother 2001;12: 367-73.
96. Hanecak R, Brown-Driver V, Fox MC, Azad RF, Furusako S, Nozaki C, et al. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol 1996; 70: 5203-12.
97. Wakita T, Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J Biol Chem 1994; 269: 14205-10.
98. Gallego J, Varani G. The hepatitis C virus internal ribosome-entry site: a new target for antiviral research. Biochem Soc Trans 2002; 30: 140-6.
99. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999; 6: 937-43.
100. Baize S, Marianneau P, Georges-Courbot MC, Deubel V. Recent advances in vaccines against viral haemorrhagic fevers. Curr Opin Infect Dis 2001; 14: 513-8.
101. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, et al, Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002; 298: 146-59.
102. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 2001; 34: 417-23.
103. Forns X, Allander T, Rohwer-Nutter P, Bukh J. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface. Virology 2000; 274: 75-85.
104. Ma X, Forns X, Gutierrez R, Mushahwar I, Wu T, Payette P, et al. DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine 2002; 20: 3263.
105. Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000; 32: 618-25.
106. Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000; 32: 618-25.
107. Beckebaum S, Cicinnati VR, Gerken G. DNA-based immuno-therapy: potential for treatment of chronic viral hepatitis? Rev Med Virol 2002; 12: 297-319.
108. Zhu J, Wang CL, Zhu LX, Kong YY, Wang Y, Li GD. DNA immunization with recombinant HCV E2 expression plasmids. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002; 34: 445-51.
109. Brinster CF, Inchauspe G. DNA vaccines for hepatitis C virus. Intervirology 2001; 44: 143-53.
110. Thibeault D, Maurice R, Pilote L, Lamarre D, Pause A. In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus. J Biol Chem 2001; 276: 46678-84.
111. Kang LW, Cho HS, Cha SS, Chung KM, Back SH, Jang SK, et al. Crystallization and preliminary X-ray crystallographic analysis of the helicase domain of hepatitis C virus NS3 protein. Acta Crystallogr D Biol Crystallogr 1998; 54: 121-3.
112. Hwang J, Fauzi H, Fukuda K, Sekiya S, Kakiuchi N, Shimotohno K, et al. The RNA aptamer-binding site of hepatitis C virus NS3 protease. Biochem Biophys Res Commun 2000; 279: 557-62.
113. Kumar PK, Machida K, Urvil PT, Kakiuchi N, Vishnuvardhan D, Shimotohno K, et al. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 1997; 237: 270-82.
114. Macejak DG, Jensen KL, Jamison SF, Domenico K, Roberts EC, Chaudhary N, et al. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 2000; 31: 769-76.
115. Zhang H, Hanecak R, Brown-Driver V, Azad R, Conklin B, Fox MC, et al. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob Agents Chemother 1999; 43: 347-53.
116. Forns X, Bukh J. The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin Liver Dis 1999; 3: 693-716.
117. Murakami K, Abe M, Kageyama T, Kamoshita N, Nomoto A. Down-regulation of translation driven by hepatitis C virus internal ribosomal entry site by the 3′ untranslated region of RNA. Arch Viral 2001; 146: 729-41.